Pharmaceutical Executive Daily: FDA Approves Braftovi

Feb 25, 05:51 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk and GSK announce major deal activity in a mergers and acquisitions roundup, and UK regulators confiscate thousands of doses of illegal weight-loss medicines.

Share
Subscribe
Next
Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive